HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

candesartan cilexetil (Amias)

Subscribe to New Research on candesartan cilexetil

a prodrug which is metabolized to an active form (CV-11974) to exert its biological effects

Also Known As:

Amias; Atacand; Kenzen; 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate; Almirall brand of candesartan cilexetil; Astra brand of candesartan cilexetil; AstraZeneca brand of candesartan cilexetil; Blopress; Parapres; Promed brand of candesartan cilexetil; TCV 116; TCV-116; Takeda brand of candesartan cilexetil; 1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-

Networked: 306 relevant articles (53 outcomes, 91 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Asmar, R: 5 articles (01/2009 - 11/2000)
2.	Michelson, E L: 5 articles (07/2001 - 04/2000)
3.	Trenkwalder, P: 4 articles (01/2005 - 01/2000)
4.	Matsuoka, H: 4 articles (10/2001 - 01/2001)
5.	Kobayashi, N: 4 articles (10/2001 - 01/2001)
6.	Widdop, Robert E: 3 articles (01/2012 - 05/2003)
7.	Bramlage, Peter: 3 articles (01/2011 - 01/2009)
8.	Bönner, Gerd: 3 articles (01/2011 - 05/2004)
9.	Sugaya, Takeshi: 3 articles (10/2005 - 03/2002)
10.	Salvetti, Massimo: 3 articles (04/2005 - 11/2002)

Related Diseases

1.	Hypertension (High Blood Pressure) 06/01/2001 - "Thus, candesartan cilexetil either alone or as add-on therapy was highly effective for the control of systolic or diastolic hypertension regardless of demographic background when used in typical clinical practice settings." 10/15/1998 - "In conclusion, candesartan cilexetil administered once daily effectively reduces BP in a dose-related manner while maintaining safety and tolerability; doses of 16 and 32 mg are most effective for treatment of hypertension." 01/01/2001 - "Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy." 01/01/2010 - "Therapy with candesartan cilexetil 0.05, 0.20, and 0.40 mg/kg/day for 4 weeks was effective in the treatment of hypertension in children aged 1 to <6 years, inducing significant dose-dependent reductions from baseline in sitting SBP (SSBP) [primary endpoint] and sitting DBP (SDBP) in the double-blind phase of a randomized, parallel-group, multinational, dose-ranging clinical study. " 01/01/2002 - "The efficacy of candesartan cilexetil is not affected by age, and the drug provided significant BP reductions in Black patients and in those with severe hypertension. "
2.	Heart Failure 01/01/2004 - "ARCH-J study showed that candesartan cilexetil, 8 mg/day, significantly improved the progression of heart failure when compared with placebo." 01/01/2000 - "Initial clinical studies have indicated that candesartan cilexetil is well tolerated and effective in patients with heart failure. " 01/01/2000 - "Administration of candesartan cilexetil reduces cardiac preload and afterload and is expected to be useful for the treatment of congestive heart failure." 10/01/2003 - "This 6-month study examined the safety and efficacy of candesartan cilexetil, 8 mg once daily, to prevent the progression of congestive heart failure (CHF). " 01/01/2005 - "Candesartan cilexetil: a review of its use in the management of chronic heart failure."
3.	Stroke (Strokes) 01/01/2006 - "The use of candesartan cilexetil as part of antihypertensive therapy in elderly patients with elevated blood pressure was also deemed to be cost effective in a Swedish analysis, primarily resulting from a reduced risk of nonfatal stroke (as shown in the SCOPE study); however, the generalisability of results to other contexts has not been established. " 09/01/2011 - "Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study." 07/01/2003 - "The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke. " 07/01/2003 - "The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors." 04/01/2004 - "Acute candesartan cilexetil therapy in stroke survivors."
4.	Fibrosis (Cirrhosis) 02/01/2009 - "Surprisingly, the degree of cardiac fibrosis in candesartan cilexetil-treated SDT rats was less than that of SD rats. " 09/01/2003 - "Candesartan cilexetil treatment significantly reduced the fibrosis development. " 05/01/2000 - "Experiments were conducted to determine the effects of ET(A) receptor antagonism (A-127722) and AT(1) receptor antagonism (candesartan cilexetil) on the development of renal fibrosis and the decline of renal function. " 01/01/1994 - "We investigated the preventive effect of an AII receptor antagonist, TCV-116, on the development of cardiac hypertrophy and fibrosis in spontaneously hypertensive rats (SHR) at 24 weeks of age through histopathological study and an AII receptor assay. " 12/01/1997 - "Stroke-prone spontaneously hypertensive rats were given candesartan cilexetil, a specific non-peptide AT1-receptor antagonist, for 10 weeks, and cardiac phenotypic and fibrosis-related gene expression and aortic and mesenteric arterial gene expressions were determined. "
5.	Cardiomegaly (Heart Hypertrophy) 10/01/1997 - "Another AT1 receptor antagonist, candesartan cilexetil (1 or 3 mg/kg/day for 2 weeks), also prevented this type of cardiac hypertrophy. " 04/01/1996 - "AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats." 12/01/1995 - "TCV-116 also suppressed cardiac hypertrophy. " 01/01/1994 - "We conclude that TCV-116 can prevent neointimal formation after balloon injury as well as reducing blood pressure and preventing cardiac hypertrophy." 10/01/1998 - "These findings suggest that candesartan cilexetil 2-8 mg/day orally for 8-12 weeks is beneficial in the regression of cardiac hypertrophy in patients with essential hypertension."

Related Drugs and Biologics

1.	Hydrochlorothiazide (Esidrix)
2.	Enalapril
3.	candesartan cilexetil (Amias)
4.	Collagen Type I (Type I Collagen)
5.	Losartan (Cozaar)
6.	Angiotensin II
7.	Messenger RNA (mRNA)
8.	candesartan
9.	Type 1 Angiotensin Receptor
10.	Amlodipine (Norvasc)

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Stents
3.	Transplants (Transplant)
4.	Renal Dialysis (Hemodialysis)
5.	Denervation